China-based clinical research SaaS service provider AlphaLife Sciences has reportedly raised “tens of millions” of US dollars in a Series A+ financing round. The round was led by Hankang Capital, with participation from B Capital. The proceeds will be used to further develop and expand the company’s next-generation clinical study cloud platform.
Company Background and Platform Development
Founded in 2020, AlphaLife Sciences is dedicated to making life science clinical study scenarios and links informational and intelligent. The company’s team members come from leading tech and life science companies, including Google, Verily, Splunk, Medidata, Veeva, and Wuxi Apptec. In May 2021, AlphaLife Sciences launched its next-generation clinical study cloud platform, AuroraPrime 1.0 system, followed by an RMB 100 million (USD 13.9 million) Series A funding round two months later. The AuroraPrime 2.0 system was launched online in May of this year, enabling integrated and informational clinical protocol writing.
Future Outlook
The Series A+ financing round underscores AlphaLife Sciences’ commitment to advancing its clinical research platform. By leveraging the new funds, the company aims to enhance its technology, expand its market presence, and provide more efficient and intelligent solutions for clinical research.-Fineline Info & Tech
